Drugs / Copper Cu 64-DOTA-pembrolizumab
Copper Cu 64-DOTA-pembrolizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05728372 | Aug 2023 → Nov 2026 | metastatic malignant neoplasm | City of Hope Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper Cu 64-DOTA-pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05728372 ↗ |
| Known as | 64CDP | “This clinical trial tests how well using 64Cu-DOTA pembrolizumab (64CDP) with positron emission tomography (PET) scans works to find tumor cells in patients with cancers that...” NCT05728372 ↗ |
| Known as | 64Cu-DOTA pembrolizumab | “This clinical trial tests how well using 64Cu-DOTA pembrolizumab (64CDP) with positron emission tomography (PET) scans works to find tumor cells in patients with cancers that...” NCT05728372 ↗ |